Karen Weintraub is a Senior Health Reporter at USA Today. She covers a wide range of medical issues, including infectious diseases, genetics, neuroscience, and cancer, with a strong focus on healthcare administration, patient care, public health, oncology, and mental health care. Karen's work has been featured in several prominent publications, including the Detroit Free Press, Chicago Sun-Times, and Yahoo News.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Karen Weintraub's articles primarily focus on health, healthcare, pharmaceuticals, medical advancements, diseases, treatments, and medical research with a national (United States) geographic emphasis. She often cites data in her coverage.
To effectively reach out to Karen with pitches or expert sources related to the latest medical advancements and breakthroughs in the United States would be ideal. Additionally, providing insight into how specific diseases are being tackled through innovative treatments and medical research could also catch her attention. Given her focus on citing data and government announcements, offering credible statistical analyses or viewpoints on new regulations impacting healthcare may resonate well with her reporting style.
It is important to note that Karen’s coverage leans towards scientific topics related to health care which can include groundbreaking therapies and their impact as well as challenges within the U.S. healthcare system.
This information evolves through artificial intelligence and human feedback. Improve this profile .
American Journeys: This medical odyssey gave him a new lease on life
By: Karen Weintraub
American Journeys: This medical odyssey gave him a new lease on life
By: Karen Weintraub
Amgen has asked the FDA to review evidence that its drug Tavneos (avacopan), which treats a rare form of vasculitis, is worth keeping on the market.
By: Karen Weintraub
Gilead and Merck's HIV data: The duo will present more detailed results of the Phase 3 trials of their once-weekly oral …
